- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT03718338
Mechanisms of Metabolic and Hormone Action on Plaque Formation in Brain and Carotid Vessels in Patients With Prostate Adenocarcinoma
Mechanisms of Metabolic and Hormone Action on Plaque Formation in Brain and Carotid Vessels in Men Undergoing Androgen Deprivation Therapy
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
OUTLINE:
Patients undergo clinical evaluations over 12 months including physical exam and vital signs, waist to hip circumference, medical history and events, laboratory evaluations, imaging evaluations, cognitive function evaluations, gait assessment, and quality of life questionnaires.
Studietype
Inschrijving (Werkelijk)
Contacten en locaties
Studie Locaties
-
-
Washington
-
Seattle, Washington, Verenigde Staten, 98109
- Fred Hutch/University of Washington
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Kind
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Beschrijving
Inclusion Criteria:
- Signed informed consent
- Histologically confirmed adenocarcinoma of the prostate
- Non-castrate disease with a serum testosterone level >= 50 ng/dL (1.73 nmol/L) at baseline
- No evidence of distant metastatic disease on baseline computed tomography-chest, abdomen and pelvis (CT-CAP) and bone scans
Patients will be stratified by the presence or absence of pre-existing cardiovascular disease defined as at least one of the following:
- Prior myocardial infarction >= 30 days before enrollment
Prior revascularization procedure >= 30 days before consent, including:
- Coronary artery stent placement or balloon angioplasty
- Coronary artery bypass graft surgery
- Stent placement or balloon angioplasty to a carotid, iliac, femoral, or popliteal artery
- Carotid endarterectomy surgery
- Vascular bypass surgery of the iliac, femoral, or popliteal artery
- Results from angiogram or CT angiogram of coronary, carotic, iliac, femoral, or popliteal arteries that documents at least one vascular stenosis >= 50% at any time point before enrollment
- Carotid ultrasound results that shows stenosis >= 50% at any time point before enrollment
- Ankle-brachial pressure index < 0.9 at any time point before enrollment
- Intent to initiate continuous androgen deprivation therapy (ADT) for at least 12 months
Exclusion Criteria:
- No prior treatment with ADT at time of study entry. (Prior neoadjuvant/adjuvant ADT is allowed only if the last injection of a depot formulation wore off at least 12 months prior to enrollment)
- Previous or concurrent hormonal or systemic therapy for prostate cancer including: anti-androgens, estrogens, megestrol acetate, ketoconazole, abiraterone, enzalutamide, or chemotherapy. (Prior or planned neoadjuvant bicalutamide for prevention of tumor flare is allowed)
- Plans to start or continue treatment with an investigational product after enrollment
- Poorly controlled type 1 or type 2 diabetes mellitus, based on hemoglobin A1c, as judged by the investigator
- Prior or planned surgical castration
- Poorly controlled hypertension at time of study entry, as judged by the investigator
- Myocardial infarction or stroke < 30 days prior to enrollment
- Coronary, carotid, or peripheral artery revascularization < 30 days prior to enrollment
- Planned or scheduled cardiac surgery or percutaneous coronary intervention (PCI) procedure that is known at the time of enrollment
- Mental incapacity or language barrier precluding adequate understanding or cooperation
- Inability to tolerate magnetic resonance imaging (MRI) imaging, or both Lupron and Degarelix
- Any other clinically significant disorder which may affect the subject's health or the outcome of the trial as judged by the investigator
- Estimated glomerular filtration rate (eGFR) < 45
- History of allergy to gadolinium contrast agent
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
|---|---|
|
Clinical Evaluations
Patients undergo clinical evaluations over 12 months including physical exam and vital signs, waist to hip circumference, medical history and events, laboratory evaluations, imaging evaluations, cognitive function evaluations, gait assessment, and quality of life questionnaires.
|
Nevenstudies
Undergo clinical evaluations
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in visual characterization of 18F-florbetapir (Amyvid) positron emission tomography (PET) scans results after Andorgen Deprivation Therapy
Tijdsspanne: 12 Months
|
Change From Baseline visual characterization scan results at 12 months
|
12 Months
|
|
Change standardized uptake values of 18F-florbetapir (Amyvid) positron emission tomography (PET) scans results
Tijdsspanne: 12 Months
|
Change from baseline standardized uptake values in select regions of interest at 12 months
|
12 Months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Cognitive test results: Story recall
Tijdsspanne: 12 months
|
Change in baseline Story Recall results at 12 months
|
12 months
|
|
Cognitive Test Results: Change in Montreal Cognitive Assessment (MOCA)
Tijdsspanne: 12 Months
|
Change in baseline MOCA score results at 12 months
|
12 Months
|
|
Cognitive Test Results: Change in Clinical Dementia Rating Scale
Tijdsspanne: 12 Months
|
Change in baseline Clinical Dementia Rating Scale score at 12 months
|
12 Months
|
|
Cognitive Test Results: Digit span
Tijdsspanne: 12 Months
|
Change in baseline Digit span results at 12 months
|
12 Months
|
|
Cognitive Test Results: Letter number sequencing
Tijdsspanne: 12 Months
|
Change in baseline Letter number sequencing results at 12 months
|
12 Months
|
|
Cognitive Test Results: Stroop Test Results
Tijdsspanne: 12 Months
|
Change in baseline Stroop Test Results at 12 months
|
12 Months
|
|
Cognitive Test Results: Symbol Digit Modalities Test
Tijdsspanne: 12 Months
|
Change in baseline Symbol Digit Modalities Test score at 12 months
|
12 Months
|
|
Cognitive Test Results: Visuo-Spatial Learning Test
Tijdsspanne: 12 Months
|
Change in baseline Visuo-Spatial Learning Test results at 12 months
|
12 Months
|
|
Cognitive Test Results: Rey auditory verbal learning test (RVLT)
Tijdsspanne: 12 Months
|
Change in baseline Rey auditory verbal learning test (RVLT) score at 12 months
|
12 Months
|
|
Inflammatory and immune markers: Change in CRP
Tijdsspanne: 12 Months
|
Change in baseline CRP values at 12 months
|
12 Months
|
|
Inflammatory and immune markers: Change in IGFBP3
Tijdsspanne: 12 Months
|
Change in baseline IGFBP3 at 12 months
|
12 Months
|
|
Inflammatory and immune markers: Change in IGFBP1
Tijdsspanne: 12 Months
|
Change in baseline IGFBP1 at 12 months
|
12 Months
|
|
Inflammatory and immune markers: Change in IGF-1
Tijdsspanne: 12 Months
|
Change in baseline IGF-1 at 12 months
|
12 Months
|
|
Inflammatory and immune markers: Change in IL-6
Tijdsspanne: 12 Months
|
Change in baseline IL-6 at 12 months
|
12 Months
|
|
Metabolic Markers: Change in HgbA1C
Tijdsspanne: 12 Months
|
Change in baseline HgbA1C at 12 months
|
12 Months
|
|
Metabolic Markers: Change in Estradiol
Tijdsspanne: 12 Months
|
Change in baseline Estradiol at 12 months
|
12 Months
|
|
Metabolic Markers: Change in Follicle Stimulating Hormone (FSH)
Tijdsspanne: 12 Months
|
Change in baseline Change in Follicle Stimulating Hormone (FSH) at 12 months
|
12 Months
|
|
Metabolic Markers: Change in Leptin
Tijdsspanne: 12 Months
|
Change in baseline Leptin at 12 months
|
12 Months
|
|
Metabolic Markers: Change in Adiponectin
Tijdsspanne: 12 Months
|
Change in baseline Adiponectin at 12 months
|
12 Months
|
|
Metabolic Markers: Change in homeostatic model assessment of insulin resistance (HOMA-IR)
Tijdsspanne: 12 Months
|
Change in baseline HOMA-IR values at 12 months; Calculated based on fasting glucose and insulin test results.
|
12 Months
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Evan Yu, Fred Hutch/University of Washington Cancer Consortium
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- RG1001903
- 9939 (FHCRC)
- NCI-2018-01618 (Register-ID: CTRP)
- 5P30CA015704 (Subsidie/contract van de Amerikaanse NIH)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .